<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-2-2-4-1">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Definitive care in severe aplastic anaemia:<br /> immunosuppressive therapy
			</div>


			<div class="content-container">

					<ul>
						<li><span>IST is the first line of definitive treatment for severe aplastic anaemia patients who lack a matched sibling donor or may not be good candidates for HSCT<sup>1</sup></span></li>
						<li><span>Haematopoietic response to IST ranges from 50% to 80%<sup>1,2</sup></span></li>
						<li><span>The standard regimen consists of horse antithymocyte globulin (h-ATG) and ciclosporin (CsA)<sup>1,3</sup></span>
							<ul>
								<li><span>The precise mechanism of action of ATG remains unclear<sup>4</sup></span></li>
								<li><span>Rabbit ATG (r-ATG) became more frequently used instead of h-ATG for the following reasons<sup>5</sup></span>
									<ul>
										<li><span>Greater lymphotoxicity of r-ATG versus h-ATG</span></li>
										<li><span>Efficacy of r-ATG as a salvage therapy for relapsed or refractory severe aplastic anaemia<sup>6,7</sup></span></li>
									</ul>
								</li>
								<li><span>However, a pivotal, large prospective study suggested poorer outcomes following r-ATG compared with h-ATG, which prompted a revival of h-ATG use<sup>8</sup></span></li>
							</ul>
						</li>
						<li><span>Relapse after IST may occur in a third of patients with severe aplastic anaemia<sup>9</sup></span></li>
						<li><span>Development of cytogenetic abnormalities and associated clinical disorders usually occurs within 2–4 years of IST<sup>10</sup></span></li>
					</ul>


			</div>

		</div>

		<div class="information-overlay overlay">
			
			<header>Definitive care in severe aplastic anaemia: immunosuppressive therapy </header>
			
			<ul>
				<li><span>ATG is a polyclonal immunoglobulin known to react with a number of cell types including T cells and natural killer cells, as well as molecules that modulate the immune response<sup>11</sup></span>
					<ul>
						<li><span>It is thought to block lymphocyte-mediated suppression of haematopoiesis</span></li>
					</ul>
				</li>
				<li><span>Ciclosporin inhibits T-cell activation by blocking the transcription of cytokine genes involved in inflammation, including IL-2<sup>12</sup></span></li>
				<li><span>ATG administration may cause adverse effects including:<sup>10</sup></span>
					<ul>
						<li><span>Infusion-related toxicity, manifested as fevers, rigors, urticarial cutaneous eruption and, in some cases, hypotension and hypoxaemia</span></li>
						<li><span>Serum sickness 1–2 weeks after administration of ATG</span></li>
						<li><span>Increases in liver enzymes; these normalise over several days</span></li>
					</ul>
				</li>
				<li><span>CsA may cause:<sup>10</sup> </span>
					<ul>
						<li><span>Hypertension</span></li>
						<li><span>Gingival hyperplasia, particularly when calcium channel blockers are co-administered to treat CsA-associated hypertension</span></li>
						<li><span>Corticosteroids or antihistamines may be co-administered with an ATG infusion to reduce the risk of an allergic reaction<sup>3</sup></span></li>
					</ul>
				</li>
				<li><span>Cytogenetic abnormalities in severe aplastic anaemia occurs at an approximate rate of 10–15% per 10 years<sup>13</sup></span>
					<ul>
						<li><span>It may be due to inadequate IST, which results in refractory severe aplastic anaemia and preservation of genetically abnormal cells<sup>6,14</sup></span></li>
						<li><span>Disorders resulting from these cytogenetic abnormalities include monosomy 7, high-grade MDS, complex karyotype and leukaemia<sup>10</sup></span></li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/module2/DeZernA-2011-ExpertRevHematol-v4p221.pdf"><span>DeZern AE & Brodsky RA. <i>Exp Rev Hematol</i> 2011;4:22</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/GuinanEC-2011-HematolAmSocHematolEducProgram-v2011p76.pdf"><span>Guinan EC. <i>Hematology Am Soc Hematol Educ Program</i> 2011;2011:76</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/BacigalupoA-2009-HematolOncolClinNAm-v23p159.pdf"><span>Bacigalupo A & Passweg J. <i>Haematol Oncol Clin N Am</i> 2009;23:159</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/YoungNS-2008-CurrOpinHematol-v15p162.pdf"><span>Young NS <i>et al. Curr Opin Hematol</i>. 2008;15:162</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-HematologyAmSocHematolEducPogram-v2012p292.pdf"><span>Scheinberg P. <i>Hematology Am Soc Hematol Educ Program</i> 2012;292</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2006-BrJHaematol-v133p622.pdf"><span>Scheinberg P <i>et al. Br J Haematol</i> 2006;133:622</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/DiBonaE-1999-BrJHaematol-v107p330.pdf"><span>Di Bona E <i>et al. Br J Haematol</i> 1999;107:330</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2011-NEJM-v365p430.pdf"><span>Scheinberg P <i>et al. N Eng J Med</i> 2011;365:430</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/YoungNS-2006-Blood-v108p2509.pdf"><span>Young NS<i> et al. Blood</i> 2006;108:2509</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Scheinberg P <i>et al. Blood</i> 2012;120:1185</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/PasswegJ-2011-JClinOncol-v29p303.pdf"><span>Passweg J <i>et al. J Clin Oncol</i> 2011;29:303</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/MatsudaS-2000-Immunopharmacology-v47p119.pdf"><span>Matsuda S & Koyasu S. <i>Immunopharmacology</i> 2000;47:119</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/MaciejewskiJ-2004-LeukLymph-v45p433_MK.pdf"><span>Maciejewski JP & Selleri C. <i>Leukaemia & Lymphoma</i> 2004;45:433</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AfableM-2011-HematolAmSocHematolEducProgram-v2011p90.pdf"><span>Afable MG <i>et al. Hematology Am Soc Hematol Educ Program</i> 2011;90</span></li>
			</ol>

		</div>

	</div>
</div>